OraSure Technologies

OSUR · NASDAQ

$3.75+$0.065 (+1.77%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $3.68

Latest news

NewsAug 28, 12:43 PM ET
World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency
Press releaseAug 5, 4:05 PM ETGlobe Newswire
OraSure Announces Second Quarter 2026 Financial Results
Press releaseJul 22, 4:10 PM ETGlobe Newswire
OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th
Press releaseJul 21, 4:30 PM ETGlobe Newswire
OraSure Receives Emergency Use Authorization for Second Generation Ebola Test
Press releaseJun 11, 8:00 AM ETGlobe Newswire
OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections
NewsMay 15, 5:06 PM ET
12 Health Care Stocks Moving In Friday's After-Market Session
NewsMay 6, 5:03 PM ET
Earnings Scheduled For May 6, 2026
Press releaseMay 6, 4:05 PM ETGlobe Newswire
OraSure Announces First Quarter 2026 Financial Results
Press releaseApr 22, 4:10 PM ETGlobe Newswire
OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th
NewsMar 24, 5:05 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
NewsMar 18, 10:39 AM ETVandana Singh
Altai Capital Presses OraSure Board For Overhaul, Nominates Two Directors
NewsMar 17, 4:54 PM ET
OraSure Defends Strategy Amid Altai Proxy Push; Highlights 2026 Regulatory, Commercial Milestones And Shareholder Value Initiatives
Press releaseMar 17, 4:52 PM ETGlobe Newswire
OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital
Press releaseMar 17, 9:15 AM ETBusiness Wire
Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance
NewsMar 17, 8:17 AM ET
'Altai Vows To Press On With Proxy Fight If Orasure Does Not Offer Board Seats; Investor Altai Capital Calls On Orasure Technologies To Put Itself Up For Sale, Letter Says' - Reuters Exclusive
Press releaseFeb 25, 4:05 PM ETGlobe Newswire
OraSure Announces Fourth Quarter 2025 Financial Results
Press releaseFeb 10, 8:05 AM ETGlobe Newswire
OraSure to Launch OraQuick™ HIV Self-Test in Canada
Press releaseJan 15, 8:30 AM ETBusiness Wire
Altai Capital Management Nominates Two Highly-Qualified Candidates for Election to OraSure Board of Directors
Press releaseJan 5, 8:00 AM ETGlobe Newswire
OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review
Press releaseDec 17, 8:00 AM ETBusiness Wire
Altai Capital Management Announces Intention to Nominate Two Highly-Qualified Candidates for Election to OraSure Board of Directors
NewsAug 5, 4:32 AM ET
Earnings Scheduled For August 5, 2025

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency

OraSure Announces Second Quarter 2026 Financial Results

OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th

OraSure Receives Emergency Use Authorization for Second Generation Ebola Test

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

12 Health Care Stocks Moving In Friday's After-Market Session

Earnings Scheduled For May 6, 2026

OraSure Announces First Quarter 2026 Financial Results

OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th

12 Health Care Stocks Moving In Tuesday's After-Market Session

Altai Capital Presses OraSure Board For Overhaul, Nominates Two Directors

OraSure Defends Strategy Amid Altai Proxy Push; Highlights 2026 Regulatory, Commercial Milestones And Shareholder Value Initiatives

OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital

Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance

'Altai Vows To Press On With Proxy Fight If Orasure Does Not Offer Board Seats; Investor Altai Capital Calls On Orasure Technologies To Put Itself Up For Sale, Letter Says' - Reuters Exclusive

OraSure Announces Fourth Quarter 2025 Financial Results

OraSure to Launch OraQuick™ HIV Self-Test in Canada

Altai Capital Management Nominates Two Highly-Qualified Candidates for Election to OraSure Board of Directors

OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review

Altai Capital Management Announces Intention to Nominate Two Highly-Qualified Candidates for Election to OraSure Board of Directors

Earnings Scheduled For August 5, 2025